12:19 PM EST, 01/13/2025 (MT Newswires) -- (Updates with the stock price move in the headline and the first paragraph, and FactSet estimates in the second paragraph.)

Madrigal Pharmaceuticals ( MDGL ) shares were down nearly 12% in recent trading on Monday after the company posted Q4 net sales estimates ahead of analysts' consensus.

The company reported preliminary Q4 Rezdiffra net sales of $100 million to $103 million. Analysts polled by FactSet expect $89.8 million.

The company also reported preliminary yearend 2024 cash, cash equivalents, restricted cash and marketable securities of about $931 million.

Price: 298.51, Change: -40.40, Percent Change: -11.92